Novavax, Inc. (NVAX) Stock Analysis & Investment Frameworks
Novavax, Inc. (NVAX) stock analysis on Invetso. Review Novavax, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Novavax, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Novavax, Inc. Key Financial Metrics
- Market Cap: $1.60B
- Revenue: $1.12B
- P/E Ratio: 3.64
- ROE: 159.85%
- ROIC: -36.14%
- Dividend Yield: N/A
About Novavax, Inc.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Novavax, Inc. Investment Frameworks
Invetso analyzes Novavax, Inc. (NVAX) across the following frameworks:
- Novavax, Inc. 10Y Growth Potential
- Novavax, Inc. Scenario Analysis
- Novavax, Inc. Risks & Opportunities
- Novavax, Inc. Economic Moat
- Novavax, Inc. Business Model
- Novavax, Inc. Management
- Novavax, Inc. SWOT Analysis
- Novavax, Inc. Porter's 5 Forces
- Novavax, Inc. PESTLE Analysis
- Novavax, Inc. ESG Analysis